Mechanism of PERK - eIF2a Pathways in Intestinal Mucosal Barrier of IBS-D and the Role "Metabolism Ingredients" of Tongxieyaofang

NCT04122586 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

IBS (Irritable Bowel Syndrome)

Interventions

DRUG: Tongxieyaofang(granule)

Sponsor

Xiyuan Hospital of China Academy of Chinese Medical Sciences